We examined thrombospondin-1 (THBS1, alias TSP-1) expression in human synovial tissue (ST) during the resolution phase of chronic
inflammation and elucidated its transcriptional regulation by the orphan receptor 4A2 (NR4A2). In vivo,
rheumatoid arthritis (RA) serum and ST revealed altered expression levels and tissue distribution of
TSP-1. After anti-
tumor necrosis factor therapy, a reciprocal relationship between
TSP-1 and NR4A2 expression levels was measured in patients with clinical and ST responses to
biological treatment. In vitro, primary RA fibroblast-like synoviocytes (FLSs) expressed minimal
TSP-1 mRNA levels with high transcript levels of NR4A2,
vascular endothelial growth factor (
VEGF), and
IL-8 measured. Hypoxic modulation of RA FLSs resulted in inverse expression levels of
TSP-1 compared with NR4A2,
IL-8, and
VEGF. Ectopic NR4A2 expression led to reduced
TSP-1 mRNA and
protein levels with concomitant increases in proangiogenic mediators. NR4A2 transcriptional activity, independent of
DNA binding, repressed the hTSP-1 promoter leading to reduced
mRNA and
protein release in immortalized K4IM FLSs. Bioinformatic and deletion studies identified a 5' region of the
TSP-1 promoter repressed by NR4A2 and proangiogenic
transcription factors, including NF-κB and Ets1/2. Stable depletion of NR4A2 levels resulted in a shift in the TSP-1/
VEGF expression ratio. Thus, modulation of
TSP-1 expression is achieved through anti-
tumor necrosis factor therapy effects on specific transcriptional networks, suggesting that enhanced
TSP-1 expression may help restore tissue homeostasis during resolution of
inflammation.